Life Without Diabetes

Sponsor
University Hospital, Gentofte, Copenhagen (Other)
Overall Status
Completed
CT.gov ID
NCT02212665
Collaborator
(none)
59
1
5
47
1.3

Study Details

Study Description

Brief Summary

The aim of the study 'Live - without diabetes' is to investigate the effects of increased physical activity on a daily basis with or without (high intense interval training) HIIT (short and intense: 3 minutes per week) during 12 weeks in risk individuals with pre-diabetes

Condition or Disease Intervention/Treatment Phase
  • Behavioral: High intense interval training
  • Behavioral: Increased daily activity detected by the pedometer
  • Behavioral: Increased daily activity detected by the pedometer+HIIT
  • Behavioral: Increased daily activity detected by the pedometer+group intervention
N/A

Detailed Description

A total of 125 individuals with pre-diabetes will be included and randomized into four different groups (N=25, each group): 1) Increased daily activity detected by the pedometer, 2) increased daily activity detected by the pedometer + HIIT, 3) HIIT, and 4) increased daily activity detected by the pedometer + group intervention 5) a control group (maintain unchanged activity and life-style during the duration of the study).

Study Design

Study Type:
Interventional
Actual Enrollment :
59 participants
Allocation:
Randomized
Intervention Model:
Factorial Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Life Without Diabetes
Study Start Date :
Jan 1, 2014
Actual Primary Completion Date :
Dec 1, 2017
Actual Study Completion Date :
Dec 1, 2017

Arms and Interventions

Arm Intervention/Treatment
Experimental: High intense interval training (HIIT)

3 x 20 sec, 3 x week

Behavioral: High intense interval training

Experimental: Increased daily activity detected by the pedometer

10.000 steps a day

Behavioral: Increased daily activity detected by the pedometer

Experimental: Increased daily activity detected by te pedometer+HIIT

10.000 steps + 3 x 20 sec, 3 x week

Behavioral: Increased daily activity detected by the pedometer+HIIT

Experimental: Increased daily activity (pedometer)+group intervention

10.000 steps + group intervention

Behavioral: Increased daily activity detected by the pedometer+group intervention

No Intervention: Control group

Outcome Measures

Primary Outcome Measures

  1. Changes in insulin sensitivity [At baseline and after 12 weeks]

    The primary endpoint is insulin sensitivity, and it will be assessed by changes in the area under the curve from baseline to end-of-study assessed by the Cederholm Index and Matsuda Index

Secondary Outcome Measures

  1. Changes in oxygen peak oxygen uptake [At baseline and after 12 weeks]

    Assessed from a physical fitness test (VO2peak)

  2. Changes in glycaemic control [At baseline and after 12 weeks]

    Measured as fasting plasma glucose, HbA1c

  3. Changes in key proteins in glucose and fat metabolism (Skeletal muscle) [At baseline and after 12 weeks]

    Expression/content of key proteins in skeletal muscle tissure (AU units)

  4. Changes in body weight (kg) [At baseline and after 12 weeks]

    Measured by Dual-energy X-ray Absorptiometry, DXA

  5. Changes in key proteins in glucose and fat metabolism (Adipose fat tissure) [At baseline and after 12 weeks]

    Expression/content of key proteins in adipose tissue (AU units)

  6. Patient-reported outcome measure [At baseline and after 12 weeks]

    Health related quality of life measured from Short Form 36 (SF36). Where scores are presented as norm-based scores (0-100) with higher scores indicating better perceived health status.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Body mass index (BMI) > 25 kg/m2

  • Prediabetes: 6.1 % ≤ glycated hemoglobin A1c (HbA1c) ≤ 6.4 % and / or increased fasting plasma glucose (FPG): 6.1 mM ≤ FPG ≤ 6.9 mM and / or abnormal glucose tolerance (7.8 mM ≤ 2 hour plasma glucose (PG) ≤ 11.0 mmol)

  • Weekly training status <150 minutes

Exclusion Criteria:
  • BMI <25 kg/m2

  • Diabetes

  • Pregnancy and breastfeeding

  • Treatment with medicine, there influence glucose metabolism

  • Decreased liver function (liver transaminases > 3 times of limit of normal)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Center for Diabetes Research, Gentofte Hospital Hellerup Denmark 2900

Sponsors and Collaborators

  • University Hospital, Gentofte, Copenhagen

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Pernille Mensberg, MSc, ph.d-student, University Hospital, Gentofte, Copenhagen
ClinicalTrials.gov Identifier:
NCT02212665
Other Study ID Numbers:
  • H-4-2013-079
First Posted:
Aug 8, 2014
Last Update Posted:
Jul 9, 2021
Last Verified:
Jul 1, 2021
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 9, 2021